

LEI: 213800H188ZDCWWXFA21

21 October 2024

**Creo Medical Group plc**  
("Creo" or the "Company")

**Director/PDMR Share Dealings**

Further to the announcements made on 30 September 2024 and 18 October 2024, and pursuant to the recent fundraising, the Company confirms that the following directors of the Company have acquired New Ordinary Shares at the Issue Price of 24 pence per Ordinary Share as follows:

Director/PDMR Name	No. of New Ordinary Shares Acquired	Resultant Shareholding post transaction	% of voting rights post transaction
Kevin Crofton	2,916,666	3,566,666	0.87%
Richard Rees	208,333	3,036,540	0.74%

**Creo Medical Group plc**  
Richard Craven, Company Secretary

[www.creomedical.com](http://www.creomedical.com)  
Via Walbrook PR

**Cavendish Capital Markets Limited**  
(Nominated Adviser, Joint Bookrunner and Joint Broker)  
Stephen Keys / Camilla Hume / George Lawson  
(NOMAD)  
Michael Johnson (Sales)

+44 (0)20 7220 0500

**Deutsche Numis (Joint Bookrunner and Joint Broker)**  
Freddie Barnfield / Duncan Monteith / Euan Brown  
William Baunton (ECM)

+44 (0)20 7260 1000

**Walbrook PR Ltd**

Tel: +44 (0)20 7933 8780

Paul McManus / Phillip Marriage

or [creo@walbrookpr.com](mailto:creo@walbrookpr.com)

Mob: +44 (0)7980 541 893 / +44 (0)7867 984

082

**NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM**

1	<b>Details of the person discharging managerial responsibilities / person closely associated</b>	
a)	Name	Kevin Crofton
2	<b>Reason for the notification</b>	
a)	Position/status	Non-Executive Chairman
b)	Initial notification/Amendment	Initial Notification
3	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	Creo Medical Group plc
b)	LEI	213800H188ZDCWWXFA21
4	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	

a)	Description of the financial instrument, type of instrument	Ordinary shares of £0.001 each	
	Identification code	GB00BZ1BLL44	
b)	Nature of the transaction	Purchase of Ordinary Shares	
c)	Price(s) and volumes(s)	Price(s)	Volume(s)
		£0.24	2,916,666
d)	Aggregated information	N/A single transaction	
	Aggregated volume	N/A single transaction	
	Price	N/A single transaction	
e)	Date of the transaction	21 October 2024	
f)	Place of the transaction	London Stock Exchange	

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>		
a)	Name	Richard Rees	
<b>2</b>	<b>Reason for the notification</b>		
a)	Position/status	Chief Financial Officer	
b)	Initial notification/Amendment	Initial Notification	
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	Creo Medical Group plc	
b)	LEI	213800H188ZDCWWXFA21	
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument	Ordinary shares of £0.001 each	
	Identification code	GB00BZ1BLL44	
b)	Nature of the transaction	Purchase of Ordinary Shares	
c)	Price(s) and volumes(s)	Price(s)	Volume(s)
		£0.24	208,333
d)	Aggregated information	N/A single transaction	
	Aggregated volume	N/A single transaction	
	Price	N/A single transaction	
e)	Date of the transaction	21 October 2024	
f)	Place of the transaction	London Stock Exchange	

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHGCBGDGUGDDGSB